This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): piperacillin sodium and tazobactam for injection, Tazocin (EU), Tazobac (EU), Tazonam (EU), YP-18 (Japan)
Description: Zosyn is an intravenous antibiotic combination product consisting of Piperacillin (a semisynthetic penicillin) and Tazobactam. Piperacillin exerts bactericidal activity by inhibiting bacterial septum and cell wall formation, while Tazobactam is a ß-lactamase inhibitor.
Zosyn has a broad spectrum of bactericidal activity against gram- positive and gram-negative aerobic and anaerobic organisms. It is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam-susceptible strains of indicated organisms.
Deal Structure: Zosyn was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion.
In October 2009, Pfizer completed its acquisition of Wyeth.
Partners: Otsuka Holdings Co., Ltd. Toyama Chemical Co., Ltd.
Additional information available to subscribers only: